Europe
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
Companies including Sanofi, J&J, Nestle have dropped out.
A look at three biotech companies that face make-or-break catalysts this year.
AstraZeneca did not immediately respond to a request for comment.
Failing numbers are putting a strain on CEO Pascal Soriot’s pledge of achieving $45B of annual revenue by 2023.
The company goes “above and beyond” with staggering 7% or greater dividend raises over 25 years.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board.
Only a week after launch, Partner Therapeutics acquired the global rights to Leukine from Sanofi.
The SEC filed a suit against “one or more unknown traders” while it seeks to identify the perpetrators.
PRESS RELEASES